Evidence map›Paper›PMID 41105754›Full record

ArticleScience immunology2025

Simultaneous induction of multiple classes of broadly neutralizing antibody precursors by combination germline-targeting immunization in nonhuman primates.

Henry J Sutton, Krystal M Ma, Jon M Steichen, Torben Schiffner, Tasha K Altheide, Alessia Liguori, Danny Lu, Michael Kubitz, Erik Georgeson, Nicole Phelps and 10 more

Abstract read
In one paragraph

Article in Science immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Antibody feedback establishes an affinity brake in the germinal center.bioRxiv : the preprint server for biology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Henry J SuttonCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-6472-7116
Krystal M MaConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-6519-2531
Jon M SteichenConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-4586-3251
Torben SchiffnerConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.
Tasha K AltheideCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.
Alessia LiguoriConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-8606-574X
Danny LuConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-2340-3377
Michael KubitzConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.
Erik GeorgesonConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-5137-4625
Nicole PhelpsConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-9613-3921
Ryan TingleConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2874-7010
Nushin B AlaviConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-3848-6280
Elana Ben-AkivaKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-1085-5902
Xiaoya ZhouIAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0001-5074-5815
Carolyne KifudeIAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA.
Claudia T FlynnIAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0009-0003-3067-6781
Eva RakaszWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0001-8197-5309
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0002-8637-1405
William R SchiefConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-1120-0150
Shane CrottyCenter for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.ORCID 0000-0002-6484-6262

Funding

Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6M
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIVR01AI147826 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SCHIFFNER, TORBEN · 2019 to 2025
$8.0M
NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
NIAID NIH HHS R01 AI147826NIAID NIH HHS UM1 AI144462NIH HHS P51 OD011106NIH HHS S10 OD025052
6 · The paper itself

Abstract

Inducing broadly neutralizing antibodies (bnAbs) against HIV remains a key challenge in vaccine development. Germline-targeting immunogens have effectively primed bnAb B cell lineages to individual HIV envelope epitopes in humans and nonhuman primates. However, eliciting consistent bnAb breadth requires the induction of multiple bnAb classes. We investigated whether immunization with a combination of germline-targeting immunogens could concurrently prime multiple bnAb lineages in nonhuman primates. Animals were immunized with three immunogens, targeting distinct epitopes: the V3-glycan/N332 supersite, the V2 Apex region, and the membrane-proximal external region (MPER), either individually or in combinations of two or all three. Triple combination immunization transiently reduced V2 Apex and V3-glycan responses, but by 8 weeks postboost, bnAb precursor lineages were observed to all three epitopes. Similar somatic hypermutation was observed across groups, indicative of permissive germinal center responses. These findings support combination germline-targeting immunization as a viable strategy to prime multiple bnAb lineages simultaneously.

Indexed as

AIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV-1HIV AntibodiesHIV InfectionsAnimalsFemaleHumansImmunizationMacaca mulattaAIDS VaccinesAntibodies, NeutralizingBroadly Neutralizing AntibodiesHIV Antibodies

Identifiers

PMID41105754
PMCPMC12687666

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.